CN101374833B - 新型吡喃酮-吲哚衍生物及其制备方法 - Google Patents

新型吡喃酮-吲哚衍生物及其制备方法 Download PDF

Info

Publication number
CN101374833B
CN101374833B CN2007800039654A CN200780003965A CN101374833B CN 101374833 B CN101374833 B CN 101374833B CN 2007800039654 A CN2007800039654 A CN 2007800039654A CN 200780003965 A CN200780003965 A CN 200780003965A CN 101374833 B CN101374833 B CN 101374833B
Authority
CN
China
Prior art keywords
ring
preparation
pyrone
salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800039654A
Other languages
English (en)
Chinese (zh)
Other versions
CN101374833A (zh
Inventor
莫什·劳顿
塔尔·派莱格舒尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of CN101374833A publication Critical patent/CN101374833A/zh
Application granted granted Critical
Publication of CN101374833B publication Critical patent/CN101374833B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
CN2007800039654A 2006-02-15 2007-02-13 新型吡喃酮-吲哚衍生物及其制备方法 Active CN101374833B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77332206P 2006-02-15 2006-02-15
US60/773,322 2006-02-15
PCT/IB2007/000330 WO2007093880A2 (en) 2006-02-15 2007-02-13 Novel pyrone-indole derivatives and process for their preparation

Publications (2)

Publication Number Publication Date
CN101374833A CN101374833A (zh) 2009-02-25
CN101374833B true CN101374833B (zh) 2012-06-27

Family

ID=38283075

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800039654A Active CN101374833B (zh) 2006-02-15 2007-02-13 新型吡喃酮-吲哚衍生物及其制备方法

Country Status (21)

Country Link
US (3) US7635710B2 (enExample)
EP (1) EP1991541B1 (enExample)
JP (1) JP5248332B2 (enExample)
KR (1) KR101207736B1 (enExample)
CN (1) CN101374833B (enExample)
AU (1) AU2007216226B2 (enExample)
BR (1) BRPI0706992C8 (enExample)
CA (1) CA2642465C (enExample)
DK (1) DK1991541T3 (enExample)
EA (1) EA015605B1 (enExample)
ES (1) ES2428873T3 (enExample)
IL (1) IL193236A (enExample)
NO (1) NO339826B1 (enExample)
NZ (1) NZ569797A (enExample)
PL (1) PL1991541T3 (enExample)
PT (1) PT1991541E (enExample)
SI (1) SI1991541T1 (enExample)
TW (1) TWI501960B (enExample)
UA (1) UA104988C2 (enExample)
WO (1) WO2007093880A2 (enExample)
ZA (1) ZA200806799B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CN103319467B (zh) * 2013-06-15 2015-10-14 湖南科技大学 一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途
JP6428645B2 (ja) * 2014-01-14 2018-11-28 アステラス製薬株式会社 インドール化合物
RU2561045C1 (ru) * 2014-07-15 2015-08-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный университет" (ФГБОУ ВПО "КубГУ") Нейропротекторное фармакологическое средство
US9567510B2 (en) 2014-09-11 2017-02-14 Halliburton Energy Services, Inc. Cyanamide-based carbon dioxide and/or hydrogen sulfide scavengers and methods of use in subterranean operations
DK3261640T3 (da) 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
EP3503884B1 (en) * 2016-08-23 2021-07-21 Neurim Pharmaceuticals Ltd. Pharmaceutical composition for use in treating pruritus and/or itch
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
WO2021229566A1 (en) * 2020-05-11 2021-11-18 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Compositions of tryptophol derivatives and 4-ethyl-phenol derivatives, and methods of using same
WO2022238905A1 (en) * 2021-05-11 2022-11-17 Neurim Pharmaceuticals (1991) Ltd. Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus
US12674575B1 (en) * 2023-01-13 2026-07-07 Cliffie L. Fitts Candle holder structure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1352545A (zh) * 1999-05-27 2002-06-05 纽里姆药品(1991)有限公司 吲哚衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA222247A (en) 1922-08-15 Hubert Rogers Reginald Pocket container for confections
IT1196849B (it) 1986-02-16 1988-11-25 Rotta Research Lab Nuovi derivati degli acidi 5 pentilammino 5 oxo pentaoico e 4 pentilammino 4 oxo butanoico ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
AU8876591A (en) 1990-11-02 1992-05-26 Upjohn Company, The Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
EP0841063A1 (en) * 1996-03-27 1998-05-13 Toray Industries, Inc. Ketone derivatives and medicinal use thereof
EP1324993A2 (en) * 2000-04-18 2003-07-09 Cytovia, Inc. Substituted 1,4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof
PE20060303A1 (es) 2004-06-23 2006-05-19 Wyeth Corp Metabolitos de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
US7834050B2 (en) * 2006-03-29 2010-11-16 Duke University Small molecule insulin mimetics absent quinones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1352545A (zh) * 1999-05-27 2002-06-05 纽里姆药品(1991)有限公司 吲哚衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bhim C Maiti et al.Reaction of dehydroacetic acid with aliphatic,aromatic and heterocyclic amines.《Indian Journal of Chemistry》.1998,第37B卷710-712. *
BhimCMaitietal.Reactionofdehydroaceticacidwithaliphatic aromatic and heterocyclic amines.《Indian Journal of Chemistry》.1998

Also Published As

Publication number Publication date
WO2007093880A3 (en) 2007-11-01
KR101207736B1 (ko) 2012-12-03
PT1991541E (pt) 2013-10-02
US8569355B2 (en) 2013-10-29
DK1991541T3 (da) 2013-10-28
KR20080094945A (ko) 2008-10-27
EP1991541B1 (en) 2013-07-24
BRPI0706992C1 (pt) 2021-05-18
ZA200806799B (en) 2009-10-28
AU2007216226B2 (en) 2011-02-24
EA015605B1 (ru) 2011-10-31
US20120302620A1 (en) 2012-11-29
EA200801580A1 (ru) 2009-02-27
US7635710B2 (en) 2009-12-22
US20080027121A1 (en) 2008-01-31
IL193236A (en) 2012-08-30
NZ569797A (en) 2010-06-25
NO20083905L (no) 2008-09-12
BRPI0706992A2 (pt) 2011-04-12
JP2009526831A (ja) 2009-07-23
CA2642465C (en) 2012-08-07
ES2428873T3 (es) 2013-11-12
US20100048662A1 (en) 2010-02-25
CA2642465A1 (en) 2007-08-23
AU2007216226A1 (en) 2007-08-23
SI1991541T1 (sl) 2014-02-28
UA104988C2 (uk) 2014-04-10
JP5248332B2 (ja) 2013-07-31
TW200835690A (en) 2008-09-01
TWI501960B (zh) 2015-10-01
CN101374833A (zh) 2009-02-25
HK1126760A1 (en) 2009-09-11
US8242163B2 (en) 2012-08-14
EP1991541A2 (en) 2008-11-19
BRPI0706992C8 (pt) 2021-05-25
NO339826B1 (no) 2017-02-06
BRPI0706992B1 (pt) 2021-05-04
AU2007216226A2 (en) 2009-05-14
WO2007093880A2 (en) 2007-08-23
IL193236A0 (en) 2009-02-11
PL1991541T3 (pl) 2013-12-31

Similar Documents

Publication Publication Date Title
US7635710B2 (en) Pyrone-indole derivatives and process for their preparation
TWI374141B (en) Spiro-oxindole compounds and their uses as therapeutic agents
US9101613B2 (en) Methods for treating neurological disease
TW201036960A (en) Benzofuran derivatives
TW201111369A (en) Chromone derivatives, a process for their preparation and their therapeutic applications
IL176111A (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
JPWO2009123080A1 (ja) インドリノン化合物
JPWO2002006231A1 (ja) セロトニン再取り込み阻害剤
EA022776B1 (ru) Арилсульфонамиды для лечения заболеваний цнс
WO2010101128A1 (ja) アミド化合物
JP6943239B2 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
WO2023088435A1 (zh) 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
WO2021164661A1 (zh) 2-苯基环丙基甲基胺衍生物及其制备方法和用途
HK1126760B (en) Novel pyrone-indole derivatives and process for their preparation
CA2551168C (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
JP4042566B2 (ja) ピペリジン化合物およびその医薬用途
HK40034146A (en) Oxadiazole transient receptor potential channel inhibitors
HK1176619A1 (en) Sulfone compounds as 5-ht6 receptor ligands
HK1176619B (en) Sulfone compounds as 5-ht6 receptor ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1126760

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1126760

Country of ref document: HK